sur Xlife Sciences AG (isin : CH0461929603)
Strategic Alliance to Boost Korean Life Sciences Ventures' Global Reach
Xlife Sciences AG, a Swiss incubator and accelerator, has signed a strategic Memorandum of Understanding (MoU) with JIPYONG LLC, a Korean law firm, and JIPYONG IP, an intellectual property advisory firm. This partnership aims to enhance the global market access of Korean life sciences ventures by facilitating international capital markets, potential listings, and strengthened global positioning.
The MoU, signed in Seoul, involves initiatives across five strategic pillars, including company evaluation, investment facilitation, capital market advisory, IP strategy, and market intelligence sharing. This collaboration seeks to bolster the global profile of Korean biopharma and medtech companies, leveraging combined expertise for substantial growth.
Oliver R. Baumann, CEO of Xlife Sciences, emphasized the value of integrating incubation expertise with legal and IP strengths to unlock growth opportunities for Korean innovators in the global arena.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xlife Sciences AG